Han (16) identified significant activation of the FOXA2-KIT signaling axis in t-NEPC, identifying the KIT signaling pathway as a therapeutic target for NEPC, but current clinical trials of KIT inhibitors in prostate cancer have not reached valid endpoints (phase III) (74). The gene discussed is KIT; the disease is prostate carcinoma.